Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05595499 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2026 to Aug 14, 2027
    • Study completion date: Jun 1, 2026 to Aug 14, 2028
    v17
  2. Eligibility criteria expanded, about 4 wordsv16
  3. Site contacts updated at 2 of 7 sitesv15
  4. Site contacts updated at 1 of 7 sitesv14
  5. Study sites: 2 to 7v13
Show 11 earlier versionsHide 11 earlier versions
  1. Site contacts updated at 2 of 2 sitesv12
  2. Primary and study completion dates: May 15, 2025 to Jun 1, 2026v11 Show 5 more changesShow less
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 339 words
    • Secondary endpoints: 2 to 17
    • Study description expanded, about 314 words
    • Study title expanded, about 1 word
  3. Re-verified, no change to tracked fieldsv10
  4. Primary and study completion dates: Aug 14, 2025 to May 15, 2025v9
  5. Lead sponsor: City of Hope Medical Center to Jonsson Comprehensive Cancer Center
    • Study site revised
    • Collaborators: 1 to 2
    v8
  6. Primary and study completion dates: May 15, 2025 to Aug 14, 2025v7
  7. Start date changed from estimate of Mar 15, 2023 to Mar 27, 2023v6
  8. Primary and study completion dates: Dec 31, 2023 to May 15, 2025v5 Show 4 more changesShow less
    • Start date: Mar 31, 2023 to Mar 15, 2023
    • Eligibility criteria shortened, about 354 words
    • Secondary endpoints: 12 to 2
    • Study description shortened, about 197 words
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 31, 2023 to Mar 31, 2023
    • Site details revised
    v4
  10. Start date: Nov 5, 2022 to Jan 31, 2023v3
  11. Site contact updated
    • Study title shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.
Trial Details
NCT Number NCT05595499
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI), National Institute on Aging (NIA)
Conditions
(from sponsor)		 Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov